Entities / Company
Alvotech.
biotechnology company
- Reports this week
- 1
- Active events
- 0
- Connections
- 57
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
One to three months ago
-
Bank of America raised its price target following positive news regarding Alvotech, a licensing agreement for biosimilar commercialization, and the FDA closing an inspection after quality issues.Some support2 reports
-
Millennium Management increased its stake in Alvotech stock, which trades on Nasdaq, with details published on MarketBeat.Some support3 reports
-
FDA closed an inspection of Alvotech's manufacturing facility located in Reykjavik, Iceland.Some support1 report
Gone quiet
No new reports in 90+ days-
Alvotech listed on an electronic stock exchange and is seeking private placement investors in the European Economic Area.Some support9 reports
-
Alvotech announces that its corporate headquarters are located in Reykjavík.Some support1 report
-
Alvotech, a Nasdaq-listed company operating in North America and Europe, could benefit from Trump-era tariffs.Some support1 report
-
Alvotech is listed on Nasdaq for a public offering, targeting investors in the European Economic Area.Some support1 report
-
Alvotech announced significant operational developments, including reported results from Reykjavik, Iceland, and acquisitions of R&D facilities in Sweden and Ivers-Lee Group in Switzerland.Some support3 reports
-
Alvotech has established strategic partnerships in Europe, China, and Africa.Some support1 report
-
Alvotech was classified in the Biomedical and Genetics industry by Zacks Medical.Some support1 report1 development inside
-
Acquisition expands capacity for Alvotech and Ivers-Lee Group while Trump-era tariffs benefit AI stocks.Some support5 reports
-
Alvotech's AVT23 is a biosimilar to Xolair.Speculative3 reports
-
A biosimilar treatment from Alvotech was approved in Europe on June 23, 2025.Speculative1 report
-
Joseph McClellan joined Alvotech as Chief Scientific Officer on June 25, 2025.Speculative1 report
-
Lenders agreed to reduce interest rates involving Alvotech and GoldenTree Asset Management.Speculative1 report
-
Alvotech and Advanz Pharma Holdco Limited entered into a supply and commercialization agreement on July 1, 2025.Speculative1 report
-
Alvotech is headquartered in Luxembourg.Speculative2 reports
-
Alvotech, Dr. Reddy’s, Sanofi, and ALK-Abelló announced expanded partnerships and product launches in India.Some support1 report
-
Teva and Alvotech formed a strategic partnership on August 1, 2025.Some support2 reports
-
Alvotech appointed Patrik Ling as VP of Investor Relations, while DNB Carnegie covered life science companies including Alvotech.Some support1 report
-
Alvotech, a UK headquartered global pharmaceutical company, received European approval for its drug Mynzepli®.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Alvotech this week
News at the entities that move Alvotech most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Alvotech
-
Iceland StructuralFrance and Canada are politically teaming up, with the French President visiting territory related to the northern hemisphere.Moves Alvotech
-
HUMIRA OperationalLost patent protection for Humira in the US on August 20, 2025.Moves Alvotech
-
European Economic Area StructuralZurich Insurance Group plans to acquire Beazley in an all-cash deal, pending review by the European Commission regarding competition in the EEA market.Moves Alvotech
-
GoldenTree Asset Management TransactionalMark Carney promoted companies, including GoldenTree Asset Management and Lightspeed, to foreign investors as part of a refinancing proposal.Moves Alvotech
-
Stockholm StructuralHemnet, Sweden's largest property portal, is based in Stockholm.Moves Alvotech
Connections
The 18 strongest of 57, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Iceland Structural
Alvotech operates, manufactures, and maintains its headquarters and market listing within Iceland.
-
FDA Structural
Alvotech is subject to the regulatory oversight, inspections, and approval processes of the FDA for its biosimilar products.
-
Nasdaq Structural
Alvotech is a company formally listed and trades on the Nasdaq stock exchange.
-
HUMIRA Operational
Alvotech is developing a biosimilar product intended to compete directly with Humira in the market.
-
Róbert Wessman Structural
Róbert Wessman serves as the Founder, Chairman, and CEO of Alvotech.
-
Sweden Operational
Alvotech is actively expanding its R&D and market presence in Sweden through acquisitions and stock listings.
-
Africa Operational
Alvotech maintains strategic partnerships and operational presence within the African market.
-
GoldenTree Asset Management Transactional
Alvotech secured term loan facilities from GoldenTree Asset Management.
Show all 18 connections
-
Europe Shared context
Alvotech operates and forms strategic partnerships within the European market, leveraging its regulatory and commercial context.
-
Millennium Management Transactional
Millennium Management increased its stake in Alvotech stock.
-
European Economic Area Structural
Alvotech relies on the EEA for regulatory approval and targets investors within the bloc.
-
Stockholm Structural
Alvotech relies on its listing on Nasdaq Stockholm for investor access and global expansion.
-
Incyte Operational
The two companies are identified as competitors within the healthcare market.
-
Bank of America Operational
Bank of America provides financial research coverage and adjusts price targets based on Alvotech's company news.
-
Reykjavík Shared context
Alvotech operates from its headquarters located in the city of Reykjavík.
-
MarketBeat Mentioned together
MarketBeat tracks and provides financial ratings and data coverage for Alvotech.
-
Donald Trump Structural
Alvotech's potential business benefits are tied to the policy outcomes of the Trump era.
-
North America Shared context
Alvotech conducts operations within the North American market.
History
Events by the month they beganSeptember 2026
1 eventAugust 2026
3 events- Alvotech utilized Nasdaq for its public stock listing and is currently undergoing comprehensive review by the FDA for biosimilar applications.
- Bank of America raised its price target following positive news regarding Alvotech, a licensing agreement for biosimilar commercialization, and the FDA closing an inspection after quality issues.
- Millennium Management increased its stake in Alvotech stock, which trades on Nasdaq, with details published on MarketBeat.
July 2026
1 eventShow 1 earlier month
June 2026
18 events- Alvotech listed on an electronic stock exchange and is seeking private placement investors in the European Economic Area.
- Alvotech announces that its corporate headquarters are located in Reykjavík.
- Alvotech, a Nasdaq-listed company operating in North America and Europe, could benefit from Trump-era tariffs.
- Alvotech is listed on Nasdaq for a public offering, targeting investors in the European Economic Area.
- Alvotech announced significant operational developments, including reported results from Reykjavik, Iceland, and acquisitions of R&D facilities in Sweden and Ivers-Lee Group in Switzerland.
- Alvotech has established strategic partnerships in Europe, China, and Africa.
- Alvotech was classified in the Biomedical and Genetics industry by Zacks Medical.
- Acquisition expands capacity for Alvotech and Ivers-Lee Group while Trump-era tariffs benefit AI stocks.
- Alvotech's AVT23 is a biosimilar to Xolair.
- A biosimilar treatment from Alvotech was approved in Europe on June 23, 2025.
- Joseph McClellan joined Alvotech as Chief Scientific Officer on June 25, 2025.
- Lenders agreed to reduce interest rates involving Alvotech and GoldenTree Asset Management.
- Alvotech and Advanz Pharma Holdco Limited entered into a supply and commercialization agreement on July 1, 2025.
- Alvotech is headquartered in Luxembourg.
- Alvotech, Dr. Reddy’s, Sanofi, and ALK-Abelló announced expanded partnerships and product launches in India.
- Teva and Alvotech formed a strategic partnership on August 1, 2025.
- Alvotech appointed Patrik Ling as VP of Investor Relations, while DNB Carnegie covered life science companies including Alvotech.
- Alvotech, a UK headquartered global pharmaceutical company, received European approval for its drug Mynzepli®.